tiprankstipranks
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Holding DE:38I?
Track your performance easily

Intellia Therapeutics (38I) Income Statement

12 Followers

Intellia Therapeutics Income Statement

Last quarter (Q3 2024), Intellia Therapeutics's total revenue was $9.11M, a decrease of -24.02% from the same quarter last year. In Q3, Intellia Therapeutics's net income was $-135.71M. See Intellia Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 43.09M$ 36.27M$ 52.12M$ 33.05M$ 57.99M$ 43.10M
Cost of Revenue
----$ -194.58M$ 149.47M
Gross Profit
$ 43.09M$ 36.27M$ 52.12M$ 33.05M$ 57.99M$ 43.10M
Operating Expense
$ 580.79M$ 551.57M$ 510.29M$ 300.90M$ 194.58M$ 149.47M
Operating Income
$ -537.71M$ -515.29M$ -458.16M$ -267.85M$ -136.58M$ -106.37M
Net Non Operating Interest Income Expense
$ 49.63M$ 49.83M$ 8.54M$ 1.28M$ 2.35M$ 6.83M
Other Income Expense
$ 971.00K$ -15.73M$ -24.56M$ 3.45M$ -11.57M$ -289.00K
Pretax Income
$ -518.86M$ -481.19M$ -474.19M$ -270.02M$ -134.23M$ -99.24M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
$ -4.73M$ -15.63M$ -11.08M$ -1.32M--
Net Income Common Stockholders
$ -522.49M$ -481.19M$ -474.19M$ -267.89M$ -134.23M$ -99.24M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 580.79M$ 551.57M$ 510.29M$ 300.90M-$ 298.94M
Net Income From Continuing And Discontinued Operation
$ -522.28M$ -481.19M$ -474.19M$ -267.89M$ -134.23M$ -99.53M
Normalized Income
$ -275.66M-----
Interest Expense
------
EBIT
$ -528.85M$ -481.19M$ -458.16M$ -267.85M$ -136.58M$ -99.24M
EBITDA
$ -493.79M$ -472.22M$ -450.59M$ -260.96M$ -130.27M$ -97.38M
Currency in USD

Intellia Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis